SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT04236986

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Imaging the Neuroimmune System in PTSD With PET

In this study, individuals with and without post-traumatic stress disorder (PTSD) will undergo one positron emission tomography (PET) scan using the radiotracer [11C]PBR28, which binds to the 18kDa translocator protein (TSPO). A subset of individuals who complete the first PET [11C]PBR28 scan will be invited to complete an inflammatory challenge and second PET [11C]PBR28 scan. Approximately 3 hours prior to the second [11C]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response. Subjects will also undergo behavioral and cognitive testing. Vital signs, subjective response, and peripheral biomarker levels will be assayed periodically throughout the experimental session. Specific aims: 1) Determine if individuals with PTSD exhibit neuroimmune system disruption relative to well-matched comparators at baseline. 2) Determine if individuals with PTSD exhibit a disrupted neuroimmune response after a classical immune stimulus relative to well-matched comparators. 3) Determine if LPS differentially alters cognitive function, subjective response, or physiological markers in individuals with PTSD compared to well-matched comparators. Hypothesis: Individuals with PTSD will exhibit a suppressed neuroimmune system at baseline and an attenuated neuroimmune response following LPS challenge.

NCT04236986 Post Traumatic Stress Disorder
MeSH: Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

1 Interventions

Name: Lipopolysaccharide

Description: LPS will be administered intravenously (1.0ng/kg; IV)

Type: Drug

Post-LPS [11C Post-LPS [11C] Post-LPS [11C]PBR28 PET Scan


Primary Outcomes

Description: Time-activity curves will be extracted from brain regions of interest and analyzed using multilinear analysis-1 (t*=30) incorporating the metabolite-corrected arterial input function to yield [11C]PBR28 total volumes of distribution (VT) across brain regions.

Measure: Baseline TSPO Availability

Time: Before LPS administration (baseline)

Description: Time-activity curves will be extracted from brain regions of interest and analyzed using multilinear analysis-1 (t*=30) incorporating the metabolite-corrected arterial input function to yield [11C]PBR28 total volumes of distribution (VT) across brain regions.

Measure: Post-LPS TSPO Availability

Time: 3-hours after LPS administration (1.0 ng/kg; IV)

Secondary Outcomes

Description: Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention). Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning). Verbal memory: # of correctly recalled items from a grocery list (3 trials). Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall). Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function). Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed). Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory). Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).

Measure: Baseline Cogstate Cognitive Battery performance

Time: Before LPS administration

Description: Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention). Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning). Verbal memory: # of correctly recalled items from a grocery list (3 trials). Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall). Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function). Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed). Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory). Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).

Measure: Post-LPS Cogstate Cognitive Battery performance

Time: Approximately 1-hour after LPS administration

Purpose: Basic Science

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 rs6971

Individuals who are classified as "low binders" for the rs6971 polymorphism (<10% of the population) Inclusion Criteria: 1. Men and women, aged 18-55 years 2. Subjects with PTSD will have a primary, current diagnosis of PTSD according to DSM-V criteria (i.e., CAPS-5 ascertained diagnosis) 3. Able to read and write English and to provide voluntary, written informed consent Exclusion Criteria: 1.

Individuals who are classified as "low binders" for the rs6971 polymorphism (<10% of the population) Post Traumatic Stress Disorder Stress Disorders, Traumatic Stress Disorders, Post-Traumatic null



HPO Nodes